Eli Lilly and Co
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A significant […]
Read More
Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August 31, 2023. Victoria Klesty | Reuters Novo Nordisk on Thursday said it sued two compounding pharmacies in Florida for allegedly selling impure and “potentially unsafe” drugs claiming to contain semaglutide, the active ingredient in […]
Read More
Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real world study says
A pharmacist displays a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly at Rock Canyon Pharmacy in Provo, Utah, May 29, 2023. George Frey | Reuters The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular treatment, Ozempic, in overweight or […]
Read More
Health care, AI and far more: How a single professional is investing for a ‘Goldilocks’ economic climate
Uncertainty in world-wide marketplaces coupled with persistently superior inflation has elevated the problem no matter whether there will be a tricky or a soft economic landing. Andy Budden, financial commitment director for equities at international monetary services agency Money Team, is in the latter camp and expects the U.S. Federal Reserve to maintain fees high […]
Read More
Hard cash is a ‘missed opportunity’ correct now, suggests one pro — here is where he’s investing as an alternative
The persistent uncertainty in economic markets, alongside with substantial curiosity premiums around the entire world, have raised the allure of keeping on to cash — but one equities qualified states this may perhaps not be the very best idea. “We are at a issue in which money deposits or revenue in hard cash and revenue […]
Read More
This key aspect of ESG investing could drive actual adjust at corporations and raise returns
A pedestrian passes a Wall Avenue subway station near the New York Stock Exchange (NYSE) in New York, U.S., on Monday, June 27, 2022. Money professionals betting on a sustained world-wide rebound will be left sorely upset in the next 50 % of this crushing yr as a protracted bear market looms, even if inflation […]
Read More
Here’s what Wall Street is saying about obesity drug Wegovy following Novo Nordisk’s key study
Analysts are largely optimistic about a new class of anti-obesity medications following a landmark study released over the weekend. Novo Nordisk ‘s Select study of about 17,500 people found the use of its Wegovy decreased the risk of serious cardiovascular complications such as heart attacks. The study, which was shared at the American Heart Association […]
Read More
Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
CFOTO | Future Publishing | Getty Images As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Analysts say upcoming data on Pfizer’s experimental obesity pill, danuglipron, will be crucial in determining how competitive the company can be against the space’s dominant players Eli Lilly and Novo Nordisk. Those […]
Read More
Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here’s why, analyst says
Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the answer is: “yes, but not to this degree.” Shin initiated coverage of a host of pharmaceutical stocks, including Eli Lilly, on Wednesday. The analyst said he is worried Lilly’s valuation is “grating against fundamentals,” as […]
Read More
Eli Lilly and a lot more: Strategist names 5 shares set for ‘significant’ earnings progress
Increasing fees and the possibility of a economic downturn on the horizon have developed a “blended photograph” for fairness marketplaces, according to one particular strategist — but numerous firms can seem forward to markedly more powerful earnings advancement in the up coming 12 months. “When you glance at what businesses are expressing about upcoming year, […]
Read More